Analyst firms Stifel and Wedbush raised their price targets and reiterated positive ratings for Micron Technology due to strong memory pricing.
1 report, 1 independent
Updated Jun 19
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analyst firms Stifel and Wedbush raised their price targets and reiterated positive ratings for Micron Technology due to strong memory pricing.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Micron Technology
American multinational corporation based in Boise, Idaho
-
Stifel
American investment bank
-
Wedbush Securities
US financial services and investment firm
Nothing else this week.
Related events
- Musk's comments on memory constraints, coupled with analyst target raises, influenced market sentiment for Micron Technology.
- Stifel reiterated a Buy rating and target price for Spyre Therapeutics, while Deutsche Bank lowered targets following company results.
- Robust demand for HBM products drove DRAM revenues in July 2025.
- Goldman Sachs released new estimates regarding the current demand trends for DRAM products.
- Spyre Therapeutics, Inc. was listed on Nasdaq and received analyst ratings from firms including Deutsche Bank and Stifel.